Vyome Holdings, Inc
HIND evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HIND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HIND
Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company developing topical and ophthalmic therapies for dermatological and immune-inflammatory conditions, with its lead candidate VT-1953 targeting malignant fungating wounds.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Vyome Holdings, Inc.
Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company developing topical and ophthalmic therapies for dermatological and immune-inflammatory conditions, with its lead candidate VT-1953 targeting malignant fungating wounds.
- Lead candidate VT-1953 is a topical gel for malignant fungating wounds, with FDA discussions on a pivotal trial design planned for Q2 2026 [sec_mda · as of 2026-03-18].
- VB-1953, for moderate to severe acne, has completed Phase II and is Phase 3-ready [sec_mda · as of 2026-08-12].
- VT-1908 is a pre-IND stage ophthalmic drop program for steroid-sparing anterior uveitis, potentially an orphan drug [sec_mda · as of 2026-08-12].
- Cash and equivalents were $7.9 million as of June 30, 2026, with the company operating under an austerity plan [sec_mda · as of 2026-08-12].
- The company has incurred significant operating losses since inception and expects to need substantial additional funding [sec_mda · as of 2026-08-12].
What works
- VT-1953 targets an unmet medical need (malignant fungating wounds) and may qualify for orphan drug designation, potentially expediting development and market exclusivity [sec_mda · as of 2026-03-18].
- VB-1953 is Phase 3-ready for moderate to severe acne, indicating a relatively advanced clinical pipeline [sec_mda · as of 2026-08-12].
- The company leverages a US-India innovation corridor, which may provide cost advantages in research and development [sec_mda · as of 2026-03-18].
What to weigh
- Cash runway is limited; as of June 30, 2026, cash was $7.9 million, and the company expects existing funds to support operations for only about 15 months, insufficient to complete a pivotal trial [sec_mda · as of 2026-08-12].
- The company has no approved products and no revenue, with significant operating losses and an accumulated deficit [sec_mda · as of 2026-08-12].
- Clinical trials may face delays due to regulatory approvals, enrollment challenges, or manufacturing issues [sec_mda · as of 2026-08-12].
- A civil notice for deferred unpaid salary of ~$95,000 highlights potential financial strain [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Lead candidate VT-1953 is a topical gel for malignant fungating wounds, with FDA discussions planned for Q2 2026.
“The lead program, VT-1953, is a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds, potentially an orphan drug designation program. The Company is planning to have discussions with the Food & Drug Administration (FDA) on a pivotal trial study design in the second quarter of 2026.”
SEC MD&A · March 18, 2026
Cash balance as of June 30, 2026, was $7,887,510.
“As of June 30, 2026, we had a cash balance of $7,887,510 and have operated under an austerity plan for several years.”
SEC MD&A · August 12, 2026
VB-1953 has completed Phase II and is Phase 3-ready.
“Another late clinical-stage program, VB1953, for moderate to severe acne, has completed its Phase II clinical trial, and this program is Phase 3-ready.”
SEC MD&A · August 12, 2026
The company expects existing cash to fund operations for about 15 months but not enough to complete a pivotal trial.
“We believe that our existing cash, together with the proceeds from the private placement offering, and proceeds from our ATM facility to date, will enable us to fund our operating expenses and capital expenditure requirements for at least 15 months, including the initiation of the pivotal trial of our lead candidate, VT-1953, but will not be sufficient to complete the trial and or work on the other indications or the development of any other product candidate.”
SEC MD&A · May 12, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $7.9M as of June 30, 2026, expected to fund only ~15 months, insufficient to complete pivotal trial [sec_mda · as of 2026-08-12].
- No approved products or revenue — Company has no marketed products and zero revenue, with significant operating losses since inception [sec_mda · as of 2026-08-12].
- Clinical trial delays — Trials may be delayed by regulatory approvals, enrollment, or manufacturing issues [sec_mda · as of 2026-08-12].
- Legal and financial liabilities — Civil notice for ~$95,000 in deferred unpaid salary indicates potential financial strain [sec_mda · as of 2026-05-12].
What to watch
- FDA discussions on pivotal trial design for VT-1953, expected in Q2 2026 [sec_mda · as of 2026-03-18].
- Ability to raise additional capital to extend runway beyond 15 months [sec_mda · as of 2026-08-12].
- Progress of VB-1953 toward Phase 3 initiation for moderate to severe acne [sec_mda · as of 2026-08-12].
- Any updates on VT-1908 pre-IND stage for anterior uveitis [sec_mda · as of 2026-08-12].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Vyome Holdings, Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vyome Holdings, Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
26.4 months
OCF -$904K · Net income -$686K
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$135K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 25,793 | $55K |
| vanguard capital management llc | 18,926 | $41K |
| vanguard fiduciary trust co | 12,195 | $26K |
| royal bank of canada | 5,856 | $13K |
| citigroup inc | 16 | $34 |
Short Interest
as of Apr 22, 2026- % of float
- 3.5%
- Days to cover
- 3.9
- Shares short
- 158,474
- Daily short volume (Jun 5, 2026)
- 39.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HIND short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vyome Holdings, Inc?
Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company developing topical and ophthalmic therapies for dermatological and immune-inflammatory conditions, with its lead candidate VT-1953 targeting malignant fungating wounds.
What is Vyome Holdings, Inc's lead drug candidate?
Vyome Holdings, Inc's most advanced tracked candidate is dbsn device (Preclinical) for type 2 diabetes mellitus.
Who is the CEO of Vyome Holdings, Inc?
Mr. Venkateswarlu Nelabhotla M.B.A. is the chief executive officer of Vyome Holdings, Inc (HIND).
Where is Vyome Holdings, Inc headquartered?
Vyome Holdings, Inc (HIND) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Vyome Holdings, Inc focus on?
Vyome Holdings, Inc develops therapies across Oncology, Ophthalmology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.